Madrigal Inks US$50 M Deal with Pfizer for DGAT-2 inhibitor Ervogastat for the Treatment of MASH
By Naini Anand
Pharma Deals Review: Vol 2026 Issue 1 (Table of Contents)
Published: 30 Jan-2026
DOI: 10.3833/pdr.v2026.i1.2994 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to strengthen its pipeline, Madrigal has signed a license agreement with Pfizer for ervogastat, a clinical-stage oral diacylglycerol O-acyltransferase 2 (DGAT-2) inhibitor for in the treatment of metabolic dysfunction-associated steatohepatitis (MASH)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS